NCT05193929已完成不适用
A Multi-center, Randomized Controlled Clinical Investigation Evaluating Wound Closure With OptiPulse™ Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers
Compedica Inc19 个研究点 分布在 2 个国家目标入组 162 人开始时间: 2021年12月15日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 162
- 试验地点
- 19
- 主要终点
- Percentage of index ulcers healed
研究概览
简要总结
The purpose of this clinical investigation is to assess the safety and performance of Compedica's OptiPulse™ and to collect subject outcome data on the treatment of diabetic foot ulcers (DFU's) versus the standard of care (SOC). OptiPulse™ is designed to enhance blood circulation in the venules and arterioles. Fibracol Plus (or equivalent) is a collagen alginate dressing that is used as the primary dressing. Both products are 510(k) FDA cleared and will be used within the cleared intended use.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 18 years old, inclusive.
- •Presence of a DFU, Wagner Grade 1 (see Appendix A for definitions) on the plantar or dorsal aspect of the foot, extending through the dermis provided it is below the medial aspect of the malleolus.
- •The index ulcer will be the largest ulcer if two or more DFUs are present with the same Wagner grade and will be the only one evaluated in the study. If other ulcerations are present on the same foot, they must be more than 2 cm distant from the index ulcer.
- •Index ulcer (i.e. current episode of ulceration) has been present for greater than 4 weeks prior to SV1 and less than 1 year, as of the date the subject consents for study.
- •Index ulcer is a minimum of 0.8 cm2 and a maximum of 25 cm2 at SV1 and TV
- •Within 3 months of SV1, adequate circulation to the affected foot, as documented by a dorsal transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg, or an Ankle Branchial Index (ABI) between 0.7 and 1.3 within 3 months of SV1, using the affected study extremity. As an alternative arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle or a TBI (Toe Brachial Index) of > 0.6 is acceptable.
- •The target ulcer has been offloaded for at least 14 days prior to randomization.
- •Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers or abstinence) during the course of the study and undergo pregnancy tests.
- •Subject understands and is willing to participate in the clinical study and can comply with weekly visits.
- •Subjects must have read and signed the IRB approved ICF before screening procedures are performed.
排除标准
- •1. Index ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes.
- •2. Index ulcer, in the opinion of the investigator, is suspicious for cancer and should undergo an ulcer biopsy to rule out a carcinoma of the ulcer.
- •3. Index ulcer is overtly infected (i.e. purulent drainage).
- •Subjects with a history of more than two weeks of treatment with immune-suppressants (including systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within 1-month prior to first SV1, or who receive such medications during the screening period or who are anticipated to require such medications during the course of the study.
- •5. Subjects on any investigational drug(s) or therapeutic device(s) within 30 days preceding SV
- •6. History of radiation at the ulcer site (regardless of time since last radiation treatment).
- •7. Index ulcer has been previously treated or will need to be treated with any prohibited therapies.
- •8. Subjects with a previous diagnosis of HIV or Hepatitis C.
- •Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment.
- •10. Osteomyelitis or bone infection of the affected foot as verified by x-ray within 30 days prior to the first screening visit. (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision).
- •11. Subject is pregnant or breast-feeding.
- •Presence of diabetes with poor metabolic control as documented with an HbA1c >12.0 within last 90 days.
- •13. Subjects with end-stage renal disease as evidenced by a serum creatinine ≥3.0 mg/dL within 6 months of randomization.
- •Presence of active Charcot Neuroarthropathy to the affected limb.
- •Any wound located entirely on the medial or lateral border of the foot.
- •Any wound located between the 1st through 4th toe interspaces.
- •Index ulcer has reduced in area by 30% or more after 14 days of SOC from SV1 to the TV1/Randomization visit.
研究组 & 干预措施
OptiPulse™
Experimental
The OptiPulse™ is designed to enhance blood circulation in the venules and arterioles in subjects with diabetic foot ulcers of the lower extremities. OptiPulse™ is supplied as a pair of footwear. One side is fitted with an offloaded and shin pumping unit and the other acts as pressure reducing footwear. Both active and non-active footwear should be worn to give balanced gait.
干预措施: OptiPulse™ (Device)
Standard of care offloading device
Active Comparator
Diabetic CAM boot
干预措施: Standard of Care offloading device (Device)
结局指标
主要结局
Percentage of index ulcers healed
时间窗: 12 weeks
次要结局
- Percentage Area Change(6 and 12 weeks)
- Time to Ulcer Healing(12 weeks)
- Changes in wound quality of life from screening visit to end of study ( per W-QoL)(12 weeks)
研究者
研究点 (19)
Loading locations...
相似试验
已完成
不适用
Safety and Effectiveness Study of Prodisc to Spinal Fusion SurgerySpinal DiseasesNCT00295009Synthes USA HQ, Inc.852
已完成
不适用
Safety and Efficacy Study Comparing ProDisc-C to ACDF Surgery to Treat SCDDSymptomatic Cervical Disc DiseaseNCT00291018Synthes USA HQ, Inc.368
终止
2 期
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNCT03840902EMD Serono Research & Development Institute, Inc.153
已完成
不适用
Clinical Investigation on the Use of Ophthalmic Solution Based on Sodium Hyaluronate in Treatment of Eye DiscomfortOcular DrynessNCT05777798SIFI SpA28
已完成
不适用
CellFX Treat & Resect Low-Risk BCC Feasibility StudyBCC - Basal Cell CarcinomaExcision MarginBCCNCT04918381Pulse Biosciences, Inc.30